Department of Protozoology, Faculty of Tropical Medicine, Mahidol University, Ratchawithi Road, Bangkok, 10400, Thailand.
Department of Medical Science, Faculty of Science, Rangsit University, Pathumthani, 12000, Thailand.
Malar J. 2022 Jul 11;21(1):216. doi: 10.1186/s12936-022-04238-y.
Plasmodium falciparum has been becoming resistant to the currently used anti-malarial drugs. Searching for new drug targets is urgently needed for anti-malarial development. DNA helicases separating double-stranded DNA into single-stranded DNA intermediates are essential in nearly all DNA metabolic transactions, thus they may act as a candidate for new drug targets against malarial parasites.
In this study, a P. falciparum 5' to 3' DNA helicase (PfDH-B) was partially purified from the crude extract of chloroquine- and pyrimethamine-resistant P. falciparum strain K1, by ammonium sulfate precipitation and three chromatographic procedures. DNA helicase activity of partially purified PfDH-B was examined by measuring its ability to unwind P-labelled partial duplex DNA. The directionality of PfDH-B was determined, and substrate preference was tested by using various substrates. Inhibitory effects of DNA intercalators such as anthracycline antibiotics on PfDH-B unwinding activity and parasite growth were investigated.
The native PfDH-B was partially purified with a specific activity of 4150 units/mg. The PfDH-B could unwind M13-17-mer, M13-31-mer with hanging tail at 3' or 5' end and a linear substrate with 3' end hanging tail but not blunt-ended duplex DNA, and did not need a fork-like substrate. Anthracyclines including aclarubicin, daunorubicin, doxorubicin, and nogalamycin inhibited the unwinding activity of PfDH-B with an IC value of 4.0, 7.5, 3.6, and 3.1 µM, respectively. Nogalamycin was the most effective inhibitor on PfDH-B unwinding activity and parasite growth (IC = 0.1 ± 0.002 µM).
Partial purification and characterization of 5'-3' DNA helicase of P. falciparum was successfully performed. The partially purified PfDH-B does not need a fork-like substrate structure found in P. falciparum 3' to 5' DNA helicase (PfDH-A). Interestingly, nogalamycin was the most potent anthracycline inhibitor for PfDH-B helicase activity and parasite growth in culture. Further studies are needed to search for more potent but less cytotoxic inhibitors targeting P. falciparum DNA helicase in the future.
恶性疟原虫对目前使用的抗疟药物已经产生了耐药性。因此,迫切需要寻找新的药物靶点来开发抗疟药物。在几乎所有的 DNA 代谢过程中,将双链 DNA 分离成单链 DNA 中间体的 DNA 解旋酶都是必不可少的,因此它们可能成为抗疟寄生虫的候选新药靶点。
在这项研究中,从氯喹和乙胺嘧啶耐药的恶性疟原虫株 K1 的粗提物中,通过硫酸铵沉淀和三种层析程序,部分纯化了恶性疟原虫的 5'到 3' DNA 解旋酶(PfDH-B)。通过测量其解开 P 标记的部分双链 DNA 的能力来检测部分纯化的 PfDH-B 的 DNA 解旋酶活性。通过使用各种底物来确定 PfDH-B 的方向性和底物偏好。研究了 DNA 嵌入剂(如蒽环类抗生素)对 PfDH-B 解旋活性和寄生虫生长的抑制作用。
天然 PfDH-B 的比活度为 4150 单位/毫克,部分纯化。PfDH-B 可以解开 M13-17-mer、M13-31-mer 带有 3' 或 5' 端悬垂尾巴的线性底物,但不能解开平头双链 DNA,也不需要叉状底物。蒽环类抗生素包括阿克拉霉素、柔红霉素、多柔比星和诺拉霉素,它们对 PfDH-B 解旋活性的抑制 IC 值分别为 4.0、7.5、3.6 和 3.1 μM。诺拉霉素是对 PfDH-B 解旋活性和寄生虫生长最有效的抑制剂(IC = 0.1 ± 0.002 μM)。
成功地进行了恶性疟原虫 5'-3' DNA 解旋酶的部分纯化和特性分析。部分纯化的 PfDH-B 不需要在恶性疟原虫 3' 到 5' DNA 解旋酶(PfDH-A)中发现的叉状底物结构。有趣的是,诺拉霉素是对 PfDH-B 解旋酶活性和寄生虫生长抑制作用最强的蒽环类抑制剂。未来还需要进一步研究,以寻找针对恶性疟原虫 DNA 解旋酶的更有效但细胞毒性更小的抑制剂。